Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

JAK2 -mutant clonal hematopoiesis is associated with venous thromboembolism

Rebecca L. Zon, Aswin Sekar, Katharine Clapham, Ohad Oren, Abhishek Niroula, Alexander G. Bick, Christopher J. Gibson, Gabriel Griffin, Md Mesbah Uddin, Donna Neuberg, Pradeep Natarajan, Benjamin L. Ebert

Blood (2024) 144 (20): 2149–2154.

https://doi.org/10.1182/blood.2024024187

Published: 2024

Includes: Supplemental data

Journal Articles

AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial

Shai O. Shimony, Heardley Murdock, Julia Keating, Christopher R. Reilly, Harrison K. Tsai, Christopher J. Gibson, Stefan Faderl, Tony Wagner, Nalina Dronamraju, Tara L. Lin, Ellen K. Ritchie, Thomas Prebet, Jorge E. Cortes, Geoffrey L. Uy, Jeffrey E Lancet, Donna S. Neuberg, Richard M. Stone, R. Coleman Lindsley

Blood (2024) 144 (Supplement 1): 60.

https://doi.org/10.1182/blood-2024-200413

Published: 2024

Journal Articles

Feasibility, Safety and Efficacy of Oral Maintenance Therapy with Venetoclax Plus Decitabine/Cedazuridine after Venetoclax Plus FluBu2 for High Risk MDS/AML Undergoing RIC Allo-HCT

Jacqueline S. Garcia, Haesook T. Kim, Jennifer Brock, H. Moses Murdock, Mahasweta Gooptu, Vincent T. Ho, Roman M. Shapiro, Christopher J. Gibson, Amar H. Kelkar, Corey S. Cutler, Denbaa Bat-Erdene, Jeremy Ryan, Anna Bosch-Vilaseca, Anthony G. Letai, Jerome Ritz, Coleman Lindsley, Robert J. Soiffer, Joseph Antin

Blood (2024) 144 (Supplement 1): 1045.

https://doi.org/10.1182/blood-2024-194170

Published: 2024

Journal Articles

Mutation-Specific Differences in the Relationship between Obesity and Clonal Hematopoiesis, with a Focus on JAK2 V617F and MPN Prevention

Blood (2024) 144 (Supplement 1): 872.

https://doi.org/10.1182/blood-2024-204211

Published: 2024

Journal Articles

Induction of Graft-Versus-Leukemia Effect with Treg-Depleted DLI Plus Ipilimumab for Myeloid Disease Relapse after HLA-Matched Transplant

Roman M. Shapiro, Haesook T. Kim, William H Terral, Vincent T. Ho, Mahasweta Gooptu, Rizwan Romee, Christopher J. Gibson, Amar H. Kelkar, Corey S. Cutler, Joseph H. Antin, Katie Maurer, Catherine J. Wu, Robert Zeiser, Jerome Ritz, Robert J. Soiffer, Sarah Nikiforow, John Koreth

Blood (2024) 144 (Supplement 1): 4833.

https://doi.org/10.1182/blood-2024-194102

Published: 2024

Journal Articles

PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy

Blood (2023) 142 (24): 2079–2091.

https://doi.org/10.1182/blood.2023020331

Published: 2023

Includes: Supplemental data

Journal Articles

Specific Clonal Mutations Are Predictive of Therapy-Related Myeloid Neoplasms (tMN) after Autologous Peripheral Blood Stem Cell Transplantation (aPBSCT) for Lymphoma

Smita Bhatia, Chengcheng Yan, Melissa A Richard, Jianbo He, Alysia Bosworth, David Crossman, Purnima Singh, Lindsey Hageman, Saro H. Armenian, Julie M. Vose, Daniel J. Weisdorf, Yutaka Yasui, Benjamin L. Ebert, Christopher J. Gibson, Stephen J Forman, Ravi Bhatia

Blood (2022) 140 (Supplement 1): 295–297.

https://doi.org/10.1182/blood-2022-165604

Published: 2022

Journal Articles

Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis

Lachelle D. Weeks, Abhishek Niroula, Donna S. Neuberg, Waihay J. Wong, R. Coleman Lindsley, Marlise R. Luskin, Nancy Berliner, Richard M. Stone, Daniel J DeAngelo, Robert J Soiffer, Md Mesbah Uddin, Christopher J. Gibson, Alexander G. Bick, Gabriel K. Griffin, Siddhartha Jaiswal, Luca Malcovati, Pradeep Natarajan, Benjamin L. Ebert

Blood (2022) 140 (Supplement 1): 2229–2231.

https://doi.org/10.1182/blood-2022-158960

Published: 2022

Journal Articles

Maintenance Therapy with Venetoclax/Azacitidine Can be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML: Results of a Phase 1 Study

Blood (2022) 140 (Supplement 1): 917–919.

https://doi.org/10.1182/blood-2022-157611

Published: 2022

Journal Articles

Prevalence of Clonal Hematopoiesis of Indeterminate Potential in Patients with Monoclonal B-Cell Lymphocytosis Compared to Untreated Chronic Lymphocytic Leukemia

Anisha V. Patel, Abirami Vijenthira, Aswin Sekar, Christopher J. Gibson, Stephen P. Martindale, Rayan Fardoun, Svitlana Tyekucheva, Stacey M. Fernandes, Binyamin A. Knisbacher, Cynthia K. Hahn, Gad Getz, Catherine J. Wu, Matthew S. Davids, Jennifer R. Brown

Blood (2022) 140 (Supplement 1): 7038–7040.

https://doi.org/10.1182/blood-2022-162707

Published: 2022

Journal Articles

Association of Clonal Hematopoiesis of Indeterminate Potential with Time to First Treatment, Incidence of Richter's Syndrome, and Overall Survival in Patients with Chronic Lymphocytic Leukemia

Abi Vijenthira, Aswin Sekar, Christopher J. Gibson, Stephen P. Martindale, Rayan Fardoun, Svitlana Tyekucheva, Yue Ren, Stacey M. Fernandes, Binyamin A. Knisbacher, Cynthia K. Hahn, Gad Getz, Catherine J. Wu, Matthew S. Davids, Jennifer R. Brown

Blood (2022) 140 (Supplement 1): 9868–9870.

https://doi.org/10.1182/blood-2022-163273

Published: 2022

Journal Articles

Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19

Blood (2022) 140 (18): 1993–1997.

https://doi.org/10.1182/blood.2022018052

Published: 2022

Includes: Supplemental data

Journal Articles

TET2 -mutant clonal hematopoiesis and risk of gout

Blood (2022) 140 (10): 1094–1103.

https://doi.org/10.1182/blood.2022015384

Published: 2022

Includes: Supplemental data

Journal Articles

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML

Blood (2022) 139 (24): 3546–3557.

https://doi.org/10.1182/blood.2021014520

Published: 2022

Includes: Supplemental data

Journal Articles

Association of clonal hematopoiesis with chronic obstructive pulmonary disease

Peter G. Miller, Dandi Qiao, Joselyn Rojas-Quintero, Michael C. Honigberg, Adam S. Sperling, Christopher J. Gibson, Alexander G. Bick, Abhishek Niroula, Marie E. McConkey, Brittany Sandoval, Brian C. Miller, Weiwei Shi, Kaushik Viswanathan, Matthew Leventhal, Lillian Werner, Matthew Moll, Brian E. Cade, R. Graham Barr, Adolfo Correa, L. Adrienne Cupples, Sina A. Gharib, Deepti Jain, Stephanie M. Gogarten, Leslie A. Lange, Stephanie J. London, Ani Manichaikul, George T. O’Connor, Elizabeth C. Oelsner, Susan Redline, Stephen S. Rich, Jerome I. Rotter, Vasan Ramachandran, Bing Yu, Lynette Sholl, Donna Neuberg, Siddhartha Jaiswal, Bruce D. Levy, Caroline A. Owen, Pradeep Natarajan, Edwin K. Silverman, Peter van Galen, Yohannes Tesfaigzi, Michael H. Cho, Benjamin L. Ebert, for the COPDGene Study Investigators, National Heart, Lung, and Blood Institute Trans-Omics for Precision Medicine Consortium

Blood (2022) 139 (3): 357–368.

https://doi.org/10.1182/blood.2021013531

Published: 2022

Includes: Supplemental data

Journal Articles

Clonal Hematopoiesis Is Frequent and Associated with Inferior Survival Irrespective of Transplantation Strategy in Patients with Newly Diagnosed Multiple Myeloma

Adam S. Sperling, Robert Redd, Christopher J. Gibson, Peter G. Miller, Jill Corre, Philippe Moreau, Donna S. Neuberg, Mehmet K. Samur, Benjamin L. Ebert, Herve Avet-Loiseau, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 1127.

https://doi.org/10.1182/blood-2021-148050

Published: 2021

Journal Articles

The Association between Clonal Hematopoiesis and Gout

Mridul Agrawal, Abhishek Niroula, Pierre Cunin, Marie McConkey, Peter G. Kim, Waihay J. Wong, Lachelle D. Weeks, Amy E. Lin, Peter G. Miller, Christopher J. Gibson, Aswin Sekar, Donna S. Neuberg, Alexander G. Bick, Pradeep Natarajan, Peter A. Nigrovic, Deepak A. Rao, Benjamin L. Ebert

Blood (2021) 138 (Supplement 1): 595.

https://doi.org/10.1182/blood-2021-153639

Published: 2021

Journal Articles

The clinical and functional effects of TERT variants in myelodysplastic syndrome

Blood (2021) 138 (10): 898–911.

https://doi.org/10.1182/blood.2021011075

Published: 2021

Includes: Supplemental data

Journal Articles

Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis

Blood (2020) 136 (26): 3051–3055.

https://doi.org/10.1182/blood.2020008206

Published: 2020

Includes: Supplemental data

Journal Articles

Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome

Mikko Myllymäki, Robert Redd, Christopher R. Reilly, Wael Saber, Stephen R. Spellman, Christopher J. Gibson, Zhen-Huan Hu, Tao Wang, Esther H. Orr, Jaclyn G. Grenier, Maxine M. Chen, David P. Steensma, Corey Cutler, Immaculata De Vivo, Joseph H. Antin, Donna Neuberg, Suneet Agarwal, R. Coleman Lindsley

Blood (2020) 136 (26): 3070–3081.

https://doi.org/10.1182/blood.2020005397

Published: 2020

Includes: Supplemental data

NARROW

JAK2 -mutant clonal hematopoiesis is associated with venous thromboembolism

AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial

Feasibility, Safety and Efficacy of Oral Maintenance Therapy with Venetoclax Plus Decitabine/Cedazuridine after Venetoclax Plus FluBu2 for High Risk MDS/AML Undergoing RIC Allo-HCT

Mutation-Specific Differences in the Relationship between Obesity and Clonal Hematopoiesis, with a Focus on JAK2 V617F and MPN Prevention

Induction of Graft-Versus-Leukemia Effect with Treg-Depleted DLI Plus Ipilimumab for Myeloid Disease Relapse after HLA-Matched Transplant

PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy

Specific Clonal Mutations Are Predictive of Therapy-Related Myeloid Neoplasms (tMN) after Autologous Peripheral Blood Stem Cell Transplantation (aPBSCT) for Lymphoma

Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis

Maintenance Therapy with Venetoclax/Azacitidine Can be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML: Results of a Phase 1 Study

Prevalence of Clonal Hematopoiesis of Indeterminate Potential in Patients with Monoclonal B-Cell Lymphocytosis Compared to Untreated Chronic Lymphocytic Leukemia

Association of Clonal Hematopoiesis of Indeterminate Potential with Time to First Treatment, Incidence of Richter's Syndrome, and Overall Survival in Patients with Chronic Lymphocytic Leukemia

Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19

TET2 -mutant clonal hematopoiesis and risk of gout

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML

Association of clonal hematopoiesis with chronic obstructive pulmonary disease

Clonal Hematopoiesis Is Frequent and Associated with Inferior Survival Irrespective of Transplantation Strategy in Patients with Newly Diagnosed Multiple Myeloma

The Association between Clonal Hematopoiesis and Gout

The clinical and functional effects of TERT variants in myelodysplastic syndrome

Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis

Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only